Targets › CCR2
4 programs from 4 companies in 5 trials: 3 Phase 2, 1 Phase 3, 1 Phase 1; Oncology, Genitourinary, Cardiovascular; next expected readout Jul 2028.
Key functional receptor for CCL2 but can also bind CCL7, and CCL12. Also transduces signaling mediated by CCL13. (UniProt, P41597)
Open in Phaseline: the race on CCR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Dimerix Bioscience | DMX-200 (repagermanium) C-C chemokine receptor type 2 (CCR2) inhibitor | CCR2 | Phase 3 | FSGS | Dec 2029 |
| Icahn School of Medicine at Mount Sinai | BMS-813160 C-C chemokine receptor type 2 antagonist; C-C chemokine receptor type 5 antagonist | CCR2, CCR5 | Phase 2 | Non-small Cell Lung Cancer | Jul 2028 |
| QuantumLeap Healthcare Collaborative | Cenicriviroc C-C chemokine receptor type 5 antagonist; C-C chemokine receptor type 2 antagonist | CCR5, CCR2 | Phase 2 | COVID-19 | Jul 2028 |
| Washington University School of Medicine | 64CU-DOTA-ECL1i CCR2-targeting radiotracer for PET imaging | CCR2 | Phase 2 | Head and Neck Squamous Cell Carcinoma; Carotid Atherosclerosis | May 2032 |
FSGS (1) Head and Neck Squamous Cell Carcinoma (1) Carotid Atherosclerosis (1) Non-small Cell Lung Cancer (1) COVID-19 (1)
small molecule (2), mixed (2)
Dimerix Bioscience (1) Washington University School of Medicine (1) Icahn School of Medicine at Mount Sinai (1) QuantumLeap Healthcare Collaborative (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.